Immunopathogenesis of dengue virus infection

被引:233
作者
Lei, HY [1 ]
Yeh, TM
Liu, HS
Lin, YS
Chen, SH
Liu, CC
机构
[1] Natl Cheng Kung Univ, Coll Med, Dept Microbiol & Immunol, Tainan 701, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Med Technol, Tainan 701, Taiwan
[3] Natl Cheng Kung Univ, Coll Med, Dept Pediat, Tainan 701, Taiwan
关键词
dengue virus;
D O I
10.1007/BF02255946
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
Dengue virus infection causes dengue fever (DF), dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS), whose pathogeneses are not clearly understood. Current hypotheses of antibody-dependent enhancement, virus virulence, and IFN-gamma /TNF alpha -mediated immunopathogenesis are insufficient to explain clinical manifestations of DHF/DSS such as thrombocytopenia and hemoconcentration. Dengue virus infection induces transient immune aberrant activation of CD4/CD8 ratio inversion and cytokine overproduction, and infection of endothelial cells and hepatocytes causes apoptosis and dysfunction of these cells. The coagulation and fibrinolysis systems are also activated after dengue virus infection. We propose a new hypothesis for the immunopathogenesis for dengue virus infection. The aberrant immune responses not only impair the immune response to clear the virus, but also result in overproduction of cytokines that affect monocytes, endothelial cells, and hepatocytes. Platelets are destroyed by crossreactive anti-platelet autoantibodies. Dengue-virus-induced vasculopathy and coagulopathy must be involved in the pathogenesis of hemorrhage, and the unbalance between coagulation and fibrinolysis activation increases the likelihood of severe hemorrhage in DHF/DSS. Hemostasis is maintained unless the dysregulation of coagulation and fibrinolysis persists. The overproduced IL-6 might play a crucial role in the enhanced production of anti-platelet or anti-endothelial cell autoantibodies, elevated levels of tPA, as well as a deficiency in coagulation. Capillary leakage is triggered by the dengue virus itself or by antibodies to its antigens. This immunopathogenesis of DHF/DSS can account for specific characteristics of clinical, pathologic, and epidemiological observations in dengue virus infection. Copyright (C) 2001 National Science Council, ROC and S. Karger AG, Basel.
引用
收藏
页码:377 / 388
页数:12
相关论文
共 90 条
  • [41] A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys
    Kochel, TJ
    Raviprakash, K
    Hayes, CG
    Watts, DM
    Russell, KL
    Gozalo, AS
    Phillips, IA
    Ewing, DF
    Murphy, GS
    Porter, KR
    [J]. VACCINE, 2000, 18 (27) : 3166 - 3173
  • [42] HIGH-LEVELS OF INTERFERON-ALPHA IN THE SERA OF CHILDREN WITH DENGUE VIRUS-INFECTION
    KURANE, I
    INNIS, BL
    NIMMANNITYA, S
    NISALAK, A
    MEAGER, A
    ENNIS, FA
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 1993, 48 (02) : 222 - 229
  • [43] DENGUE VIRUS-INFECTION OF HUMAN SKIN FIBROBLASTS INVITRO PRODUCTION OF IFN-BETA, IL-6 AND GM-CSF
    KURANE, I
    JANUS, J
    ENNIS, FA
    [J]. ARCHIVES OF VIROLOGY, 1992, 124 (1-2) : 21 - 30
  • [44] ACTIVATION OF LYMPHOCYTES-T IN DENGUE VIRUS-INFECTIONS - HIGH-LEVELS OF SOLUBLE INTERLEUKIN-2 RECEPTOR, SOLUBLE CD4, SOLUBLE CD8, INTERLEUKIN-2, AND INTERFERON-GAMMA IN SERA OF CHILDREN WITH DENGUE
    KURANE, I
    INNIS, BL
    NIMMANNITYA, S
    NISALAK, A
    MEAGER, A
    JANUS, J
    ENNIS, FA
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1991, 88 (05) : 1473 - 1480
  • [45] Kurane I, 1992, Semin Immunol, V4, P121
  • [46] MECHANISMS OF DENGUE VIRUS-INDUCED BONE-MARROW SUPPRESSION
    LARUSSA, VF
    INNIS, BL
    [J]. BAILLIERES CLINICAL HAEMATOLOGY, 1995, 8 (01): : 249 - 270
  • [47] Dengue virus structural differences that correlate with pathogenesis
    Leitmeyer, KC
    Vaughn, DW
    Watts, DM
    Salas, R
    de Chacon, IV
    Ramos, C
    Rico-Hesse, R
    [J]. JOURNAL OF VIROLOGY, 1999, 73 (06) : 4738 - 4747
  • [48] Lin CF, 2001, J MED VIROL, V63, P143, DOI 10.1002/1096-9071(20000201)63:2&lt
  • [49] 143::AID-JMV1009&gt
  • [50] 3.0.CO